Etoricoxib, also known as Acomplia, is a selective cyclooxygenase-2 inhibitor, indicating relatively minor adverse effects in the gastrointestinal tract. Its main effects are anti-inflammatory, antipyretic and analgesic, and it is mainly indicated for the signs and symptoms of the acute and chronic phases of osteoarthritis, as well as acute gouty arthritis. For osteoarthritis, the recommended dose is 30 mg once daily, which can be increased to 60 mg once daily if it is not effective. For acute gouty arthritis, the recommended dose is 120 mg once daily for a maximum of 8 days. For its contraindications, one is hypersensitivity to any of the ingredients; the other is in patients with active gastrointestinal bleeding, ulcers, or previous recurrent ulcers and bleeding. It is also contraindicated in patients with asthma, urticaria and allergic reactions induced by taking aspirin or other NSAIDs; and in patients with congestive heart failure or confirmed ischemic heart disease, peripheral arterial disease and cerebrovascular disease.